A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II

NCT04596540 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Gout

Interventions

DRUG: SEL-212 low-dose
DRUG: SEL-212 high-dose
OTHER: Placebo

Sponsor

Swedish Orphan Biovitrum